JANX News and Press, Janux Therapeutics Inc.

2026-02-26 17:05:19 ET More on Janux Therapeutics Janux Therapeutics, Inc. (JANX) Shareholder/Analyst Call - Slideshow Janux Therapeutics: Downgrading To 'Hold' Rating After Latest Updated Phase 1 JANX007 mCRPC Data Janux Falls Back To Earth As 'Best-In-Class' Hopes ...

Continued clinical execution across TRACTr programs JANX007 and JANX008 JANX007 enrolling in Phase 1b Taxane-naïve patient population in metastatic castration-resistant prostate cancer (mCRPC) JANX008 enrolling expansion cohorts in defined tumor settings Initiated...

Evertec Inc. (EVTC) is expected to report $0.81 for Q4 2025 BioCryst Pharmaceuticals Inc. (BCRX) is expected to report $0.06 for Q4 2025 FTI Consulting Inc. (FCN) is expected to report $1.38 for Q4 2025 Arbe Robotics Ltd. (ARBE) is expected to report $-0.1 for Q4 2025 Aclaris Ther...

2026-02-25 15:41:35 ET More on small cap stocks The Fed Is Bracing For An AI Bubble Burst And Global Stagflation S&P 500, Trump, And The Markets: The Scorecard So Far, Where To Look Next Softer Inflation And Expectations For Stronger Q1 Economic Growth Push The F...

Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, today announced that the first participant has been dosed in a Phase 1 clinical study of JANX011, a CD19-targeted bispecific engineered using the compa...

2026-02-05 21:24:29 ET ... Read the full article on Seeking Alpha For further details see: Vir Biotechnology: The Low-Down On The Readouts Ahead

Janux Therapeutics, Inc., a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies based on its proprietary Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms, today annou...

2026-01-23 15:52:44 ET The last time I spoke about Bristol-Myers Squibb ( BMY ) it was with respect to a Seeking Alpha article entitled " Bristol-Myers Squibb: Increased Global Breyanzi Sales Isn't Only Hematological Product Growth ". In this article, I noted that the co...

2026-01-22 07:26:18 ET More on Janux Therapeutics, Bristol-Myers Squibb Company 44th Annual J.P. Morgan Healthcare Conference Bristol-Myers Squibb Company (BMY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript Bristol-Myers Squibb: Contrarian Buy ...

Janux Therapeutics, Inc. (Nasdaq: JANX) (“Janux”), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technologies to its Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and...